Neurodegenerative Disease Diagnostics Market Size
| Study Period | 2022 - 2030 |
| Market Size (2025) | USD 4.70 Billion |
| Market Size (2030) | USD 6.76 Billion |
| CAGR (2025 - 2030) | 7.52% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Neurodegenerative Disease Diagnostics Market Analysis
The Neurodegenerative Disease Diagnostics Market size is estimated at USD 4.70 billion in 2025, and is expected to reach USD 6.76 billion by 2030, at a CAGR of 7.52% during the forecast period (2025-2030).
Technological advancements and a growing demand for enhanced diagnostic solutions are driving the neurodegenerative disease diagnostics market expansion. As understanding deepens regarding the molecular and genetic underpinnings of conditions like Alzheimer’s and Parkinson’s, diagnostic tools are advancing. These modern tools can identify diseases at earlier stages, amplifying interventions' efficacy.
For example, a significant leap in neurodegenerative disease diagnostics is the increasing use of quantitative electroencephalography (EEG), which measures the brain's electrical activity. In August 2024, during the Alzheimer’s Association International Conference (AAIC), researchers from Advanced Brain Monitoring presented findings that highlight EEG's capability in distinguishing Alzheimer’s Disease (AD) from Frontotemporal Dementia (FTD). Their study demonstrated EEG's proficiency in identifying distinct biosignatures for both conditions, providing a non-invasive and economical means to differentiate these two dementia types, which often share similar symptoms.
Similarly, a groundbreaking April 2024 study from the National Institute of Neurological Disorders and Stroke (NINDS) indicated that a simple skin biopsy could accurately identify individuals with Parkinson’s Disease and its associated disorders, known as synucleinopathies. By analyzing skin samples for the abnormal alpha-synuclein proteins typically found in elevated levels in the brains of Parkinson’s patients, researchers achieved a high diagnostic accuracy. This significant advancement offers a minimally invasive, cost-effective, and easily reproducible method for diagnosing Parkinson’s Disease.
Historically, diagnosing such conditions required complex and expensive methods, including imaging techniques or analyses of cerebrospinal fluid. This breakthrough could transform the diagnostic landscape for Parkinson’s Disease and its related disorders, enabling earlier detection, improving diagnostic accuracy, and allowing for more targeted treatment approaches.
Moreover, in September 2024, biotechnology company Ncardia introduced a new range of ready-to-use assays designed to enhance the screening and selection process for therapeutic candidates aimed at neurodegenerative diseases. These assays focus on conditions such as Alzheimer's Disease, Parkinson’s Disease, ALS/FTD, neuroinflammation, and neurotoxicity. They are standardized and reproducible, producing robust data valuable for research and clinical applications. These assays promise to accelerate drug development and illuminate the complex mechanisms underlying neurodegenerative diseases by streamlining the therapy screening process.
Therefore, innovations in biomarkers, imaging, and diagnostic technologies are reshaping the neurodegenerative disease diagnostics market landscape.
However, the high cost of diagnosis may limit market growth during the study period.
Neurodegenerative Disease Diagnostics Market Trends
The Alzheimer's Disease Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Alzheimer's disease (AD), the foremost cause of dementia, poses considerable challenges in its diagnosis and treatment. As the global population ages, the demand for precise and timely diagnosis becomes increasingly urgent. The market for neurodegenerative disease diagnostics is rapidly advancing, emphasizing identifying biomarkers, utilizing artificial intelligence (AI), and investigating innovative non-invasive techniques such as saliva testing.
Researchers from the University of Pittsburgh have achieved a notable milestone by creating a clinical laboratory test that evaluates over 100 genetic sequences associated with Alzheimer's disease. This test, validated in November 2024, aims to enhance clinicians' ability to diagnose Alzheimer's with improved accuracy and earlier than previously possible. The Pitt researchers highlight that their platform encapsulates the diverse nature of Alzheimer's pathology, integrating genetic, metabolic, and neurodegenerative elements. By amalgamating these distinct markers, clinicians could detect Alzheimer's in its formative stages, offering patients a chance for timely interventions that may slow the disease's progression.
In addition to biomarkers, artificial intelligence (AI) plays an increasingly pivotal role in Alzheimer's diagnosis. For instance, in July 2024, researchers from the Mayo Clinic embarked on a study investigating the combination of AI with standard electroencephalogram (EEG) tests for diagnosing Alzheimer's and other neurological disorders. EEG, a non-invasive technique that measures the brain's electrical activity, has been a staple in neurological diagnostics. However, the complexities of interpreting EEG data can be challenging and time-consuming. The Mayo Clinic researchers believe that by leveraging AI to analyze EEG results, diagnosing Alzheimer's can become more streamlined and efficient. AI algorithms swiftly sift through large datasets, identifying patterns that human analysts might miss.
Saliva is gaining traction as a potential medium for Alzheimer's diagnostics. Traditional methods, such as cerebrospinal fluid (CSF) analysis or brain imaging, tend to be invasive or necessitate expensive equipment. In contrast, saliva collection is non-invasive, straightforward, and allows for repeated sampling. For instance, a study in the Aging Medicine Journal in February 2024 highlighted saliva's potential in Alzheimer's diagnostics, pinpointing specific biomarkers in saliva that align with AD pathology. Though still in the early research phase, saliva testing presents significant advantages. Its non-invasive characteristic allows for frequent sampling, positioning it as an ideal tool for monitoring disease progression over time.
The landscape of Alzheimer's diagnostics is undergoing rapid transformation. With innovations like multi-genetic diagnostic platforms, the integration of AI with EEG testing, and the promising investigation of saliva as a diagnostic medium, the field is poised for significant advancements in early detection and disease monitoring.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America's neurodegenerative disease diagnostics market is rapidly evolving, driven by an aging population, increasing disease prevalence, and advancements in diagnostic technologies. Disorders like Alzheimer's and Parkinson's challenge public health and place a heavy financial burden on the healthcare system. As these diseases progress, the demand for early, accurate, accessible diagnostic tools becomes more pressing.
Currently, approximately 7 million people in the United States are diagnosed with Alzheimer's, the leading form of dementia, as per the Alzheimer's Association 2024 report. Projections suggest this number could jump to 13 million by 2050. The rising incidence of Alzheimer's and similar neurodegenerative diseases is mainly due to the aging baby boomer demographic, putting tremendous strain on healthcare resources. In 2024, the United States is projected to spend around USD 360 billion on health and long-term care for dementia patients, with estimates indicating this could soar to nearly USD 1 trillion by 2050.
Moreover, in August 2024, researchers from the University of Minnesota introduced a visual diagnostic technique, marking a significant advancement in the early detection of neurodegenerative diseases, especially Parkinson's. Traditional methods for diagnosing Parkinson's are often reactive, detecting the disease only after symptoms manifest, which is frequently too late for effective treatment. In contrast, this visual technique employs advanced imaging and machine learning to identify subtle brain changes that occur before symptoms appear. Such breakthroughs could revolutionize early detection for Parkinson's and similar diseases, leading to better patient outcomes.
Furthermore, in July 2024, a partnership was formed between Biogen, Beckman Coulter, and Fujirebia, highlighting a significant advancement in Alzheimer's diagnostics. The three companies collaborate to develop blood-based biomarkers that detect tau pathology in the brain, a crucial sign of Alzheimer's. Tau tangles and amyloid plaques are hallmark indicators of Alzheimer's, with their presence in the brain linked to cognitive decline. Traditionally, diagnosing tau pathology has been invasive and costly, often requiring cerebrospinal fluid (CSF) tests or advanced imaging scans.
Yet, the emergence of blood-based biomarkers signals a transformative shift, making Alzheimer's diagnostics more accessible and affordable. A simple blood test for tau pathology allows for earlier diagnoses and enables doctors to monitor disease progression and treatment response, all while prioritizing patient comfort. This ability to detect and quantify tau protein levels in the blood offers a rapid, cost-effective, and less invasive option compared to current diagnostic methods, representing a significant advancement over conventional practices.
Thus, given these developments, North America's neurodegenerative disease diagnostics market is set for rapid growth in the coming years. The combination of an aging population and the rising prevalence of diseases like Alzheimer's will sustain the demand for diagnostic solutions. Furthermore, the growing preference for minimally invasive and cost-effective methods, such as blood-based biomarkers and advanced imaging techniques, will play a pivotal role in shaping the industry's future.
Neurodegenerative Disease Diagnostics Industry Overview
The market is semi-consolidated due to the presence of a few major market players. The major players use strategies like mergers and acquisitions, partnerships, collaborations, research and development investments, and new product launches to navigate global competitive challenges. Some major market players are F. Hoffmann-La Roche Ltd, GE HealthCare, Siemens Healthineers AG, Creative Biogene, and Danaher Corporation (Beckman Coulter, Inc.), among others.
Neurodegenerative Disease Diagnostics Market Leaders
-
F. Hoffmann-La Roche Ltd
-
GE HealthCare
-
Creative Biogene
-
Danaher Corporation (Beckman Coulter, Inc.)
-
Siemens Healthineers AG
- *Disclaimer: Major Players sorted in no particular order
Neurodegenerative Disease Diagnostics Market News
- October 2024: ADx NeuroSciences, a Fujirebio subsidiary specializing in biomarkers for neurodegenerative diseases, has partnered with Alamar Biosciences, known for its ultra-sensitive immunoassay technologies. The partnership aims to develop customized biomarker assay solutions using Alamar’s NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) platform and the ARGO HT System. This collaboration aims to create advanced tools to detect and quantify critical biomarkers, supporting therapeutic development for neurological diseases. The two companies combine their expertise to deliver tailored assay solutions as part of the agreement. These solutions are designed for pharmaceutical firms developing new treatments for neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis.
- August 2024: AC Immune SA, in collaboration with Life Molecular Imaging (LMI), received Fast Track Designation from the United States Food and Drug Administration (FDA) for their Tau positron emission tomography (PET) diagnostic, [18F]PI-2620. This designation has been granted for the clinical development of [18F]PI-2620 in three neurodegenerative conditions: Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).
Neurodegenerative Disease Diagnostics Industry Segmentation
As per the scope of the report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and neuron degradation leads to neurons' gradual death. The neurodegenerative disease diagnosis involves a combination of clinical evaluation and advanced imaging techniques.
The neurodegenerative disease diagnostics market is segmented into product type, application, end user, and geography. By product type, the market is segmented into diagnostic imaging and in-vitro diagnostics. By application, the market is segmented into Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
| By Product Type | Diagnostic Imaging | ||
| In-Vitro Diagnostics | |||
| By Application | Parkinson's Disease | ||
| Alzheimer's Disease | |||
| Multiple Sclerosis | |||
| Huntington's Disease | |||
| Others | |||
| By End User | Hospitals | ||
| Diagnostic Laboratories | |||
| Imaging Centers | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Diagnostic Imaging |
| In-Vitro Diagnostics |
| Parkinson's Disease |
| Alzheimer's Disease |
| Multiple Sclerosis |
| Huntington's Disease |
| Others |
| Hospitals |
| Diagnostic Laboratories |
| Imaging Centers |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Neurodegenerative Disease Diagnostics Market Research FAQs
How big is the Neurodegenerative Disease Diagnostics Market?
The Neurodegenerative Disease Diagnostics Market size is expected to reach USD 4.70 billion in 2025 and grow at a CAGR of 7.52% to reach USD 6.76 billion by 2030.
What is the current Neurodegenerative Disease Diagnostics Market size?
In 2025, the Neurodegenerative Disease Diagnostics Market size is expected to reach USD 4.70 billion.
Who are the key players in Neurodegenerative Disease Diagnostics Market?
F. Hoffmann-La Roche Ltd, GE HealthCare, Creative Biogene, Danaher Corporation (Beckman Coulter, Inc.) and Siemens Healthineers AG are the major companies operating in the Neurodegenerative Disease Diagnostics Market.
Which is the fastest growing region in Neurodegenerative Disease Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Neurodegenerative Disease Diagnostics Market?
In 2025, the North America accounts for the largest market share in Neurodegenerative Disease Diagnostics Market.
What years does this Neurodegenerative Disease Diagnostics Market cover, and what was the market size in 2024?
In 2024, the Neurodegenerative Disease Diagnostics Market size was estimated at USD 4.35 billion. The report covers the Neurodegenerative Disease Diagnostics Market historical market size for years: 2022, 2023 and 2024. The report also forecasts the Neurodegenerative Disease Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Neurodegenerative Disease Diagnostics Industry Report
Statistics for the 2025 Neurodegenerative Disease Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Neurodegenerative Disease Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
